Assessment of the Efficacy of High-Dose Toremifene 120mg Therapy for Anastorozole-resistant Postmenopausal Breast Cancer (SBCCSG-11) - Assessment of the Efficacy of High-Dose Toremifene 120mg Therapy for Anastorozole-resistant Postmenopausal Breast Cancer (SBCCSG-11)

Saitama Breast Cancer Clinical Study Group (SBCCSG)0 个研究点目标入组 40 人开始时间: 2008年1月7日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients under anti-estrogen hormone therapy 2. Patients under hormone therapy except for anastrozole 3. Patients diagnosed as inflammatory breast cancer 4. Patients with a history of deep venous thrombosis 5. Patients with serious complications A. Patients with ischemic heart disease or cardiac arrhythmia that need treatment(left ventricular hypertrophy or mild left ventricular load induced by hypertension,or mild right bundle-branch block is eligible) B. Patients with a history of myocardial infarction within 6 months onset C. Patietns with uncontrollable diabetes 6. Patients with brain metastasis 7. Patients taking raloxifen (belonging to SERM) for treatment of osteoporosis 8. Doctor's decision for exclusion

发起方

Saitama Breast Cancer Clinical Study Group (SBCCSG)